January 25th 2024
The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.
Turning Food Allergy Triggers Into Therapy: A Managed Care Lens on Immunotherapy and Targeted Biologics
1.5 Credits / Immunology
View More
Targeted Therapies for the Management of Eosinophilic Esophagitis Across the Life Cycle: The Role of the Pharmacist in Patient Identification and Optimization, featuring a Pat...
1.5 Credits / Immunology
View More
Managed Care Perspectives on the Burden of Food Allergies and Advances in Treatment
1.5 Credits / Allergy, Immunology
View More
FDA Approves Dupilumab for Children Aged 6 to 11 With Moderate to Severe Asthma
October 20th 2021Sold under the name Dupixent, dupilumab is a biologic that inhibits interleukin (IL)-4 and IL-13, which are key drivers of the type 2 inflammation that plays a major role in asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, and eosinophilic esophagitis.
Read More
Dr William "Andy" Nish on Considering Adherence When Prescribing Biologics to Patients With Asthma
August 29th 2021Switching patients with asthma to a biologic medication purely because that patient is not adherent to inhaled medications gets in the way of a physician's goal of being good stewards of patient care and finances, said William "Andy" Nish, MD.
Watch
Children Receiving IV Magnesium for Acute Asthma More Likely to Be Hospitalized
August 13th 2021Nearly 9 in 10 children given intravenous (IV) magnesium for refractory asthma ended up being admitted to the hospital, but new research suggests that may be partly due to a lack of clarity about the therapy’s safety profile.
Read More
Expert Panel Makes 7 Recommendations for Vaccinations for Children With AD Receiving Dupilumab
June 18th 2021A panel of health care professionals reviewed published literature to develop a recommendation guide to advise providers on best practices when considering vaccinations for children with atopic dermatitis (AD) on dupilumab.
Read More
Dr Jonathan Silverberg Discusses What Future Research on AD in Children Should Include
May 21st 2021Now that racial and ethnic disparities of atopic dermatitis prevalence among children have been confirmed, the next step in research will be to discover the reasons why those disparities exist, said Jonathan Silverberg, MD, PhD, MPH.
Watch